Want to see HK:0460 full AI Analyst Report?

Sihuan Pharmaceutical Holdings Group (0460) Price & Analysis

1 Followers

0460 Stock Chart & Stats

HK$0.78

-HK$0.01(-1.06%)

At close: Jul 28 4:00 PM EDT

HK$0.78

-HK$0.01(-1.06%)

Day’s Range― - ―

52-Week RangeHK$0.70 - HK$1.92

Previous CloseN/A

Volume33.84M

Average Volume (3M)32.33M

Market Cap

HK$6.72B

Enterprise ValueHK$6.90K

Total Cash (Recent Filing)HK$3.72B

Total Debt (Recent Filing)HK$969.22M

Price to Earnings (P/E)18.4

Beta1.12

Next Earnings

Apr 01, 2027

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend Yield1.51%

Share Statistics

EPS (TTM)0.03

Shares Outstanding9,329,999,000

10 Day Avg. Volume18,356,548

30 Day Avg. Volume32,334,162

Financial Highlights & Ratios

PEG Ratio-0.30

Price to Book (P/B)1.72

Price to Sales (P/S)3.85

P/FCF Ratio-46.22

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)0.08

Revenue Forecast (FY)HK$3.44B

Bulls Say, Bears Say

Bulls Say

Revenue Recovery And High MarginsThe 2025 revenue rebound and return to profitability show renewed commercial traction, while consistently high gross margins provide operating leverage. If maintained, this combination can support reinvestment, strengthen earnings conversion, and improve the company’s ability to fund growth.

Manageable LeverageFalling leverage and substantial equity relative to debt reduce balance-sheet pressure and provide resilience through business volatility. This financial cushion gives Sihuan more flexibility to sustain operations, invest in products, and manage weaker earnings periods without excessive borrowing.

Established PRC Pharmaceutical PlatformAn integrated research, manufacturing, and commercialization model gives Sihuan control across key parts of the pharmaceutical value chain. Its focus on cardiovascular and cerebrovascular therapies and hospital distribution can support recurring demand and broader adoption of successful products.

Bears Say

Weak Cash ConversionNegative operating and free cash flow despite positive reported earnings indicates weak cash conversion and reduces internally generated funding. If this persists, Sihuan may have less flexibility for product investment, debt management, and shareholder returns even when accounting profits improve.

Earnings VolatilityThe sharp swings from substantial losses to a 2025 recovery make current earnings less predictable and weaken confidence in their durability. Volatile profitability can complicate planning, limit reliable reinvestment, and leave results vulnerable to renewed pressure across the product portfolio.

Low Return On EquityA low ROE shows that the sizable equity base is not yet producing strong shareholder returns, despite improved leverage and positive earnings. Continued underutilization of capital could constrain long-term value creation and suggests the turnaround has not fully translated into efficient profitability.

Sihuan Pharmaceutical Holdings Group News

Sihuan’s Xuanzhu Biopharm Strikes Exclusive Bireociclib Deal in Thailand

Sihuan Pharmaceutical Holdings Group ( ($HK:0460) ) has issued an announcement. Sihuan Pharmaceutical’s non-wholly owned subsidiary Xuanzhu Biopharm...

18d ago

Sihuan Pharmaceutical Grants 116 Million Performance-Based Share Awards

Sihuan Pharmaceutical Holdings Group ( ($HK:0460) ) just unveiled an announcement. Sihuan Pharmaceutical Holdings Group has granted 116,150,000...

20d ago

Sihuan Pharma Launches Share Buyback as Profit Surges on Aesthetics Push

Sihuan Pharmaceutical Holdings Group ( ($HK:0460) ) has shared an update. Sihuan Pharmaceutical Holdings Group has stepped up...

25d ago

Sihuan Pharmaceutical Reshapes Leadership With CFO Exit and New Non-Executive Director

Sihuan Pharmaceutical Holdings Group ( ($HK:0460) ) has shared an announcement. Sihuan Pharmaceutical announced that Ms. Miao Guili...

26d ago

Sihuan Pharmaceutical Clarifies Board and Committee Structure

Sihuan Pharmaceutical Holdings Group ( ($HK:0460) ) has issued an announcement. Sihuan Pharmaceutical Holdings Group Ltd. has announced...

26d ago

Sihuan Pharmaceutical Leans on Aesthetics and Innovation as Generic Drug Margins Erode

Sihuan Pharmaceutical Holdings Group ( ($HK:0460) ) has shared an announcement. Sihuan Pharmaceutical reported interim revenue of RMB1,161.2...

26d ago

Sihuan Pharmaceutical Sets Board Meeting to Approve Interim Results and Dividend Plan

The latest announcement is out from Sihuan Pharmaceutical Holdings Group ( ($HK:0460) ). Sihuan Pharmaceutical Holdings Group Ltd.,...

1M ago

Sihuan Pharmaceutical Updates Bermuda Registered Office Address

Sihuan Pharmaceutical Holdings Group ( ($HK:0460) ) just unveiled an announcement. Sihuan Pharmaceutical Holdings Group Ltd. has announced...

2M ago

Sihuan Pharmaceutical Flags 217% Profit Surge on Medical Aesthetics and Portfolio Gains

Sihuan Pharmaceutical Holdings Group ( ($HK:0460) ) has shared an announcement. Sihuan Pharmaceutical has issued a positive profit...

2M ago

Sihuan’s Xuanzhu Wins NMPA NDA Acceptance for New Reflux Esophagitis Use of Anaprazole

Sihuan Pharmaceutical Holdings Group ( ($HK:0460) ) has shared an update. Sihuan Pharmaceutical Holdings Group announced that China’s...

3M ago

0460 FAQ

What was Sihuan Pharmaceutical Holdings Group Ltd.’s price range in the past 12 months?

Sihuan Pharmaceutical Holdings Group Ltd. lowest stock price was HK$0.70 and its highest was HK$1.92 in the past 12 months.

What is Sihuan Pharmaceutical Holdings Group Ltd.’s market cap?

Sihuan Pharmaceutical Holdings Group Ltd.’s market cap is HK$6.72B.

When is Sihuan Pharmaceutical Holdings Group Ltd.’s upcoming earnings report date?

Sihuan Pharmaceutical Holdings Group Ltd.’s upcoming earnings report date is Apr 01, 2027 which is in 192 days.

How were Sihuan Pharmaceutical Holdings Group Ltd.’s earnings last quarter?

Sihuan Pharmaceutical Holdings Group Ltd. released its earnings results on Aug 26, 2026. The company reported HK$0.029 earnings per share for the quarter.

Is Sihuan Pharmaceutical Holdings Group Ltd. overvalued?

According to Wall Street analysts Sihuan Pharmaceutical Holdings Group Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Sihuan Pharmaceutical Holdings Group Ltd. pay dividends?

Sihuan Pharmaceutical Holdings Group Ltd. pays a Annually dividend of HK$0.011 which represents an annual dividend yield of 1.51%. See more information on Sihuan Pharmaceutical Holdings Group Ltd. dividends here

What is Sihuan Pharmaceutical Holdings Group Ltd.’s EPS estimate?

Sihuan Pharmaceutical Holdings Group Ltd.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Sihuan Pharmaceutical Holdings Group Ltd. have?

Sihuan Pharmaceutical Holdings Group Ltd. has 9,329,999,000 shares outstanding.

What happened to Sihuan Pharmaceutical Holdings Group Ltd.’s price movement after its last earnings report?

Sihuan Pharmaceutical Holdings Group Ltd. reported an EPS of HK$0.029 in its last earnings report. Following the earnings report the stock price went down -6.322%.

Which hedge fund is a major shareholder of Sihuan Pharmaceutical Holdings Group Ltd.?

Currently, no hedge funds are holding shares in HK:0460

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Sihuan Pharmaceutical Holdings Group Ltd.

Sihuan Pharmaceutical Holdings Group Ltd. is an investment holding company that engages in the research, development, manufacture, and sale of pharmaceutical and medical aesthetic products. Its portfolio includes products for the cardio-cerebral vascular system, as well as segments for innovative medicine, generic medicine, and medical aesthetics which includes injectables, energy-based devices, and skincare solutions. The company operates primarily in the People's Republic of China, with some international presence.